AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).

Sector

Pharmaceuticals

Calendar

2024-01-11 - U.S. Currency

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

149.28USD

Average target price

167.53USD

Spread / Average Target

+12.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	-7.63%	264 B $
ELI LILLY AND COMPANY	+63.47%	538 B $
NOVO NORDISK A/S	+42.56%	430 B $
JOHNSON & JOHNSON	-12.58%	372 B $
MERCK & CO., INC.	-6.49%	263 B $
ROCHE HOLDING AG	-12.81%	232 B $
NOVARTIS AG	+1.35%	198 B $
ASTRAZENECA PLC	-9.77%	197 B $
PFIZER, INC.	-43.83%	163 B $
AMGEN INC.	+2.47%	144 B $

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2023-12-08 pm EST			5-day change	1st Jan Change
149.28 ^USD	+0.89%		+4.09%	-7.63%

Dec. 08	Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup	DJ
Dec. 08	S&P 500 Rises for Sixth Straight Week as Focus Shifts to Fed Meeting, Inflation Data	MT

Health Care Climbs as Deal Wave Seen Continuing -- Health Care Roundup	Dec. 08	DJ
S&P 500 Rises for Sixth Straight Week as Focus Shifts to Fed Meeting, Inflation Data	Dec. 08	MT
News Highlights : Top Financial Services News of the Day	Dec. 08	DJ
News Highlights : Top Company News of the Day	Dec. 07	DJ
AbbVie to focus on smaller deals after buying spree	Dec. 07	RE
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 07	MT
Sector Update: Health Care Stocks Drop Thursday Afternoon	Dec. 07	MT
AbbVie-Cerevel Deal Makes 'Strategic Sense,' Mizuho Says	Dec. 07	MT
Sector Update: Health Care	Dec. 07	MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say	Dec. 07	RE
Bain scores over tenfold return with $8.7 billion Cerevel sale	Dec. 07	RE
Global markets live: AbbVie, McDonald's, Apple, AMD, Alphabet...	Dec. 07
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook	Dec. 07	MT
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs	Dec. 07	MT
Trending : AbbVie to Buy Cerevel for $45 a Share	Dec. 07	DJ
Are rate cuts are coming early next year?	Dec. 07
Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout	Dec. 07	RE
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research	Dec. 07	MT
Transcript : AbbVie Inc., Cerevel Therapeutics Holdings, Inc. - M&A Call	Dec. 07	CI
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data	Dec. 07	DJ
AbbVie: acquisition of Cerevel Therapeutics	Dec. 07	CF
Cerevel options trading surge before AbbVie deal news raises eyebrows	Dec. 06	RE
AbbVie to buy drug developer Cerevel for $8.7 billion	Dec. 06	RE
Health Flat as Obesity-Drug Stock Craze Eases -- Health Care Roundup	Dec. 06	DJ
AbbVie Signs $8.7 Billion Deal to Acquire Cerevel Therapeutics	Dec. 06	MT